Login to Your Account



Immune Control Gets $11.3M In Series A For Serotonin Work

By Jennifer Boggs


Thursday, July 14, 2005
Immune Control Inc. raised $11.3 million in its Series A financing to develop serotonin antagonists for lymphocytic cancers and autoimmune diseases, and to begin the first two clinical programs in multiple myeloma and psoriasis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription